Name (Synonyms) | Correlation | |
---|---|---|
drug2661 | Vitamin B12 Wiki | 0.50 |
drug729 | Ddrops® products, 50,000 IU, Oral Wiki | 0.50 |
drug2086 | Resveratrol Wiki | 0.50 |
drug2717 | Zinc Citrate Wiki | 0.50 |
drug2854 | impliminting Online Distance Learning Wiki | 0.50 |
drug1620 | No interverntion Wiki | 0.50 |
drug2662 | Vitamin C Wiki | 0.15 |
drug262 | Azithromycin Wiki | 0.08 |
drug1086 | Hydroxychloroquine Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D014808 | Vitamin D Deficiency NIH | 0.22 |
D018450 | Disease Progression NIH | 0.13 |
D002318 | Cardiovascular Diseases NIH | 0.11 |
D018352 | Coronavirus Infections NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100512 | Low levels of vitamin D HPO | 0.22 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.10 |
There are 4 clinical trials
A novel coronavirus disease 2019 (COVID-19) outbreak is a global dramatic pandemic that is immeasurably impacting the communities. Due to lack of data, symptomatic management is used for COVID-19 infection including oxygen therapy and mechanical ventilation for those with severe infection. Considering immunomodulatory, anti-inflammatory anti-fibrotic and anti-oxidant actions of vitamin D, it's safety and ease of administration, as well as direct effects of vitamin D on immune cell proliferation and activity, pulmonary ACE2 expression and reducing surface tension, evaluation of vitamin D supplementation as an adjuvant therapeutic intervention could be of substantial clinical and economic significance. High prevalence of vitamin D deficiency in elderly, smokers, patients with chronic diseases and excess uptake by adipose tissue in obesity make investigations of its role as a secondary therapeutic agent in COVID-19 conceivable. It should be necessary to monitor serum 25(OH)D levels in all inpatient and outpatient populations with COVID-19 to identify the importance of maintaining or promptly increasing circulating levels of 25(OH)D into the optimal range of 100-150 nmol/L. The aim of this study is to conduct a double blind, randomized, controlled three weeks clinical trial on the efficacy of vitamin D (daily low dose versus weekly high dose) in COVID-19 patients in order to determine the relationship between baseline vitamin D deficiency and clinical characteristics and to asses patients' response to vitamin D supplementation in week three and determine its association with disease progression and recovery. Subjects who are randomized to high-dose will be asked to take 50,000 IU for two times during the first week and one dose over second and third weeks to quickly raise their serum levels. Subjects in the low-dose arm will take vitamin D 1000 IU daily for three weeks.
Description: Number of Participants whose symptoms recovered over three weeks
Measure: Symptoms recovery Time: Time from onset of intervention to day 21Description: Number of patients who required hospitalization
Measure: Hospitalization Time: Between diagnosis and day 21Description: x 109/L
Measure: Blood white blood cell count (WBC) Time: At day 0 before starting intervention and day 21 of interventionDescription: If patients required mechanical ventilation at any time after diagnosis
Measure: Duration of mechanical ventilation Time: Between diagnosis and day 21Description: Length of stay in hospital (days)
Measure: Duration of hospitalization Time: Between diagnosis and day 21Description: Number of patients who required ICU
Measure: Intensive care unit (ICU) admission Time: Between diagnosis and day 21Description: Length of stay in ICU
Measure: Duration of ICU stay Time: Between diagnosis and day 21Description: mg/L
Measure: Blood C-reactive protein (CRP) Time: Baseline and day 21Description: number of lymphocytes in 1 microliter (µL) of blood
Measure: Blood Lymphocyte count Time: Baseline and day 21Description: ng/mL
Measure: Blood Ferritin Time: Baseline and day 21Description: platelets per microliter of blood
Measure: Blood platelet count Time: Baseline and day 21Description: pg/mL
Measure: Blood interleukin-6 (IL-6) Time: Baseline and day 21Description: pg/ml
Measure: Blood Tumor Necrosis Factor alpha (TNF) Time: Baseline and day 21COVID-19 is a global pandemic. So far encouraging results have been shown in different parts of the world with the utilisation of hydroxycloroquine, zinc, and azithromycin, and early studies into some of these, plus some with Vitamin C, have also proven beneficial. Vitamin D levels have also been shown to be an important indicator to the severity of symptoms in COVID-19 patients.
Description: Composite measure: Change in severity and duration of symptoms
Measure: Symptoms Time: once daily for 15 days since enrollment/baseline at admission to hospitalDescription: total number of days in hospital since admission
Measure: Length of hospital stay Time: at 15 and 45 days since admission/ enrolmentDescription: need for invasive mechanical ventilation or mortality within 15 days from enrolment
Measure: invasive mechanical ventilation or mortality Time: any time within 15 days from enrolmentDescription: Death
Measure: Mortality Time: 15 and 45 days since enrolmentDescription: need for and number of days of invasive mechanical ventilation, in case of no need for mechanical ventilation: days=0
Measure: mechanical ventilation Time: at 15 and 45 days since enrolmentDescription: need for and number of days for humidified high-flow oxygen
Measure: oxygen Time: 15 and 45 days since enrolmentDescription: admission to ICU (intensive care unit)
Measure: ICU Time: 15 and 45 days since enrolmentDescription: days in hospital
Measure: days in hospital Time: 15 and 45 days since enrolmentDescription: days in ICU
Measure: days in ICU Time: 15 and 45 days since enrolmentDescription: need for and days of renal replacement therapy
Measure: renal replacement therapy Time: 15 and 45 days since enrolmentDescription: need for and days of Extracorporeal support
Measure: Extracorporeal support Time: 15 and 45 days since enrolmentThere is evidence that resveratrol might help fight coronavirus as well as help protect the body from the effects of disease (COVID-19) caused by the infection. In this proof-of-concept pilot study we will compare the effects of resveratrol to placebo to assess the safety of resveratrol and explore effectiveness.
Description: Proportion of study participants admitted to the hospital within 21 days of testing positive
Measure: Hospitalization rates for COVID-19 Time: 21 days from testing positive from COVID-19Description: Proportion of study participants admitted to the ICU within 21 days of testing positive
Measure: ICU Admission Rates Time: 21 days from testing positive from COVID-19Description: Proportion of study participants receiving invasive ventilation within 21 days of testing positive
Measure: Invasive Ventilation Rates Time: 21 days from testing positive from COVID-19Description: Modified BORG scale, visual analog scale for fatigue
Measure: Reported symptom severity Time: 21 days from testing positive from COVID-19Description: Diarrhea, nausea, abdominal cramping
Measure: Adverse events Time: 21 days from testing positive from COVID-19This study will measure vitamin D levels in adults with COVID 19. Participants with low levels of vitamin D will be entered into an open label trial of supplementation with vitamin D.
Description: change in level of Vitamin D, 25-Hydroxy between the two time points
Measure: Vitamin D levels Time: baseline and after two weeks of vitamin D supplementationDescription: We will calculate the change in severity of COVID 19 symptoms from baseline to 2 weeks after vitamin D supplementation
Measure: severity of COVID 19 symptoms Time: baseline and at 2 weeks after vitamin D supplementation